(Q46547397)

English

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.

scientific article published on 9 June 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Shih-Ci Ciou

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Chau-Ming Cheng

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Lyu-Han Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jhao-Hao Hong

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Ming-Yan Jheng

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Szu-Ting Ling

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Yun-Wei Lin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

0 references

publication date

9 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1448-1458

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The epidermal growth factor receptor as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Cellular pharmacology of quinone bioreductive alkylating agents

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Coordinating ERK/MAPK signalling through scaffolds and inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Persistent activation of ERK1/2 by lead acetate increases nucleotide excision repair synthesis and confers anti-cytotoxicity and anti-mutagenicity

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Basis for effective combination cancer chemotherapy with antimetabolites

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Cellular localization of human Rad51C and regulation of ubiquitin-mediated proteolysis of Rad51

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Multidisciplinary management of lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The resurgence of platinum-based cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Mechanisms of resistance to cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Targeted disruption of the Rad51 gene leads to lethality in embryonic mice

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Double bolt regulation of Rad51 by p53: a role for transcriptional repression.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Identifiers

10.1093/CARCIN/BGN130

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46547397&oldid=1247085941"